This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer: The Biotech Revaluation Is On

But what the growth mutual funds want is growth that can't be pinned down and isn't even crimped by European formulations, which had been the worry for, say, Celgene not that long ago. And these four horsemen have it.

Perhaps the best way to think about this is to recognize that these stocks are the anti-gold. Anything that could drive up gold is bad for biotech. Anything that can drive it down is good. So next time you see gold swoon and take down the whole market, we now know the total handbook for the moment: Buy more deep-in-the-money calls on Biogen Idec, Gilead Sciences, Celgene and Regeneron.

These four stocks remain the go-to stocks on any geopolitical/terror weakness in this market.

Random musings: You can see these biotech animal spirits at work on a smaller scale in Acorda Therapeutics (ACOR), which reported a potential, just a potential, breakthrough in stroke treatment, where some of the losses from a stroke might be able to be rolled back. That stock, ACOR, was up $4 today after being up almost $4 yesterday on the breakthrough. Frankly, the news is so breathtaking, I still don't think the move is over yet.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long JNJ.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,780.73 -50.03 -0.28%
S&P 500 2,063.54 -12.27 -0.59%
NASDAQ 4,772.1850 -33.1060 -0.69%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs